메뉴 건너뛰기




Volumn 46, Issue 2, 2014, Pages 215-219

Cabergoline treatment in acromegaly: Pros

Author keywords

Acromegaly; Acromegaly treatment; Cabergoline; Cabergoline treatment; Medical treatment

Indexed keywords

CABERGOLINE; GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; OCTREOTIDE;

EID: 84902345051     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0206-1     Document Type: Article
Times cited : (34)

References (39)
  • 2
    • 84995823862 scopus 로고
    • The effect of a single dose of L-dopa on pituitary hormones in acromegaly, obesity, and in normal subjects
    • R.B. Mims, R.B. Stein, J.E. Bethune, The effect of a single dose of L-dopa on pituitary hormones in acromegaly, obesity, and in normal subjects. J. Clin. Endocrinol. Metab. 37, 34-39 (1973)
    • (1973) J. Clin. Endocrinol. Metab. , vol.37 , pp. 34-39
    • Mims, R.B.1    Stein, R.B.2    Bethune, J.E.3
  • 5
    • 33845491265 scopus 로고    scopus 로고
    • Medical progress: Acromegaly
    • S. Melmed, Medical progress: acromegaly. N. Engl. J. Med. 14(355), 2558-2573 (2006)
    • (2006) N. Engl. J. Med. , vol.14 , Issue.355 , pp. 2558-2573
    • Melmed, S.1
  • 6
    • 0028146981 scopus 로고
    • A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
    • Cabergoline comparative study group
    • J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N. Engl. J. Med. 331, 904-909 (1994)
    • (1994) N. Engl. J. Med. , vol.331 , pp. 904-909
    • Webster, J.1    Piscitelli, G.2    Polli, A.3    Ferrari, C.I.4    Ismail, I.5    Scanlon, M.F.6
  • 7
    • 77952124423 scopus 로고    scopus 로고
    • Prolactinomas, Cushing's disease and acromegaly: Debating the role of medical therapy for secretory pituitary adenomas
    • B.M. Biller, A. Colao, S. Petersenn, V.S. Bonert, M. Boscaro, Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr. Disord. 10, 10 (2010)
    • (2010) BMC Endocr. Disord. , vol.10 , pp. 10
    • Biller, B.M.1    Colao, A.2    Petersenn, S.3    Bonert, V.S.4    Boscaro, M.5
  • 8
    • 0041430890 scopus 로고    scopus 로고
    • Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells
    • J.J. An, S.R. Cho, D.W. Jeong, K.W. Park, Y.S. Ahn, J.H. Baik, Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol. Cell. Endocrinol. 206, 49-62 (2003)
    • (2003) Mol. Cell. Endocrinol. , vol.206 , pp. 49-62
    • An, J.J.1    Cho, S.R.2    Jeong, D.W.3    Park, K.W.4    Ahn, Y.S.5    Baik, J.H.6
  • 10
    • 0023775877 scopus 로고
    • Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients
    • Oxf.
    • C. Ferrari, A. Paracchi, C. Romano, G. Gerevini, M. Boghen, A. Barreca, P. Fortini, A. Dubini, Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol. (Oxf.) 29, 467-476 (1988)
    • (1988) Clin. Endocrinol. , vol.29 , pp. 467-476
    • Ferrari, C.1    Paracchi, A.2    Romano, C.3    Gerevini, G.4    Boghen, M.5    Barreca, A.6    Fortini, P.7    Dubini, A.8
  • 12
    • 0030740018 scopus 로고    scopus 로고
    • Cabergoline treatment of acromegaly: A preliminary dose finding study
    • Oxf.
    • S.N. Jackson, J. Fowler, T.A. Howlett, Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin. Endocrinol. (Oxf.) 46, 745-749 (1997)
    • (1997) Clin. Endocrinol. , vol.46 , pp. 745-749
    • Jackson, S.N.1    Fowler, J.2    Howlett, T.A.3
  • 15
    • 34548462041 scopus 로고    scopus 로고
    • Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy
    • L. Vilar, M.A. Czepielewsk, L.A. Naves, G.A. Rollin, L.A. Casulari, C.E. Coelho, Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr. Pract. 13, 396-402 (2007)
    • (2007) Endocr. Pract. , vol.13 , pp. 396-402
    • Vilar, L.1    Czepielewsk, M.A.2    Naves, L.A.3    Rollin, G.A.4    Casulari, L.A.5    Coelho, C.E.6
  • 16
    • 56749098338 scopus 로고    scopus 로고
    • Clinical use of cabergoline as primary and adjunctive treatment for acromegaly
    • V.J. Moyes, K.A. Metcalfe, W.M. Drake, Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur. J. Endocrinol. 159, 541-545 (2008)
    • (2008) Eur. J. Endocrinol. , vol.159 , pp. 541-545
    • Moyes, V.J.1    Metcalfe, K.A.2    Drake, W.M.3
  • 17
    • 5544284786 scopus 로고    scopus 로고
    • Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors
    • P.U. Freda, C.M. Reyes, A.T. Nuruzzaman, R.E. Sundeen, A.G. Khandji, K.D. Post, Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 7, 21-30 (2004)
    • (2004) Pituitary , vol.7 , pp. 21-30
    • Freda, P.U.1    Reyes, C.M.2    Nuruzzaman, A.T.3    Sundeen, R.E.4    Khandji, A.G.5    Post, K.D.6
  • 19
    • 14944339645 scopus 로고    scopus 로고
    • Cabergoline decreases somatotroph adenoma size: A case report
    • M.R. Rickels, P.J. Snyder, Cabergoline decreases somatotroph adenoma size: a case report. Pituitary 7, 107-110 (2004)
    • (2004) Pituitary , vol.7 , pp. 107-110
    • Rickels, M.R.1    Snyder, P.J.2
  • 20
    • 38649113922 scopus 로고    scopus 로고
    • Remission of acromegaly following long-term therapy with cabergoline: Report of two cases
    • J.A. Verhelst, P.J. Abrams, R. Abs, Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary 11, 103-107 (2008)
    • (2008) Pituitary , vol.11 , pp. 103-107
    • Verhelst, J.A.1    Abrams, P.J.2    Abs, R.3
  • 21
    • 0033288398 scopus 로고    scopus 로고
    • Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients
    • P. Marzullo, D. Ferone, C. Di Somma, R. Pivonello, M. Filippella, G. Lombardi, A. Colao, Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1, 115-120 (1999)
    • (1999) Pituitary , vol.1 , pp. 115-120
    • Marzullo, P.1    Ferone, D.2    Di Somma, C.3    Pivonello, R.4    Filippella, M.5    Lombardi, G.6    Colao, A.7
  • 22
    • 4143066821 scopus 로고    scopus 로고
    • Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status
    • Oxf.
    • R. Cozzi, R. Attanasio, S. Lodrini, G. Lasio, Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf.) 61, 209-215 (2004)
    • (2004) Clin. Endocrinol. , vol.61 , pp. 209-215
    • Cozzi, R.1    Attanasio, R.2    Lodrini, S.3    Lasio, G.4
  • 23
    • 26644444556 scopus 로고    scopus 로고
    • Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients
    • Oxf.
    • B. Gatta, D.H. Hau, B. Catargi, P. Roger, A. Tabarin, Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin. Endocrinol. (Oxf.) 63, 477-478 (2005)
    • (2005) Clin. Endocrinol. , vol.63 , pp. 477-478
    • Gatta, B.1    Hau, D.H.2    Catargi, B.3    Roger, P.4    Tabarin, A.5
  • 24
    • 17744392005 scopus 로고    scopus 로고
    • Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly
    • D. Selvarajah, J. Webster, R. Ross, J. Newell-Price, Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 152, 569-574 (2005)
    • (2005) Eur. J. Endocrinol. , vol.152 , pp. 569-574
    • Selvarajah, D.1    Webster, J.2    Ross, R.3    Newell-Price, J.4
  • 25
    • 67651108793 scopus 로고    scopus 로고
    • Optimizing medical therapy of acromegaly: Beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide
    • R.S. Jallad, M.D. Bronstein, Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90, 82-92 (2009)
    • (2009) Neuroendocrinology , vol.90 , pp. 82-92
    • Jallad, R.S.1    Bronstein, M.D.2
  • 29
    • 0031436037 scopus 로고    scopus 로고
    • Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients
    • M. Muratori, M. Arosio, G. Gambino, C. Romano, O. Biella, G. Faglia, Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest. 20, 537-546 (1997)
    • (1997) J. Endocrinol. Invest. , vol.20 , pp. 537-546
    • Muratori, M.1    Arosio, M.2    Gambino, G.3    Romano, C.4    Biella, O.5    Faglia, G.6
  • 30
    • 77957119638 scopus 로고    scopus 로고
    • The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment
    • J. Roemmler, B. Steffin, B. Gutt, H.J. Schneider, C. Sievers, M. Bidlingmaier, J. Schopohl, The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment. Growth Horm. IGF Res. 20, 338-344 (2010)
    • (2010) Growth Horm. IGF Res. , vol.20 , pp. 338-344
    • Roemmler, J.1    Steffin, B.2    Gutt, B.3    Schneider, H.J.4    Sievers, C.5    Bidlingmaier, M.6    Schopohl, J.7
  • 31
    • 70449877776 scopus 로고    scopus 로고
    • ACROSTUDY: The first 5 years
    • P.J. Trainer, ACROSTUDY: the first 5 years. Eur. J. Endocrinol. 161(Suppl 1), S19-S24 (2009)
    • (2009) Eur. J. Endocrinol. , vol.161 , Issue.SUPPL. 1
    • Trainer, P.J.1
  • 37
    • 51649119890 scopus 로고    scopus 로고
    • Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma
    • M. Kars, V. Delgado, E.R. Holman, R.A. Feelders, J.W. Smit, J.A. Romijn, J.J. Bax, A.M. Pereira, Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. 93, 3348-3356 (2008)
    • (2008) J. Clin. Endocrinol. Metab. , vol.93 , pp. 3348-3356
    • Kars, M.1    Delgado, V.2    Holman, E.R.3    Feelders, R.A.4    Smit, J.W.5    Romijn, J.A.6    Bax, J.J.7    Pereira, A.M.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.